Summary of Significant Accounting Policies (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
|---|
| Accounting Policies [Abstract] |
|
| Schedule of Components of Marketable Securities |
The following is a summary of the components of our marketable securities and the underlying fair value input level tier hierarchy (see fair value of financial instruments) (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | As of December 31, 2025 | | Amortized
Cost | | Unrealized
Gains | | Unrealized
Losses | | Fair
Value | | Corporate stock | $ | 148 | | | $ | — | | | $ | (148) | | | $ | — | | | $ | 148 | | | $ | — | | | $ | (148) | | | $ | — | |
| | | | | | | | | | | | | | | | | | | | | | | | | As of December 31, 2024 | | Amortized
Cost | | Unrealized
Gains | | Unrealized
Losses | | Fair
Value | | Corporate stock | $ | 3,528 | | | $ | — | | | $ | (401) | | | $ | 3,127 | | | $ | 3,528 | | | $ | — | | | $ | (401) | | | $ | 3,127 | |
|
| Schedule of Accounts Receivable Net |
Accounts are written off as uncollectible at the time we determine that collections are unlikely. Accounts receivable, net is comprised of the following (in thousands): | | | | | | | | | | | | | December 31, 2025 | | December 31, 2024 | | Trade accounts receivable | $ | 2,558 | | | $ | 34,901 | | | Unbilled accounts receivable | — | | | — | | | 2,558 | | | 34,901 | | | Less allowances | (1,022) | | | (14,843) | | | Total accounts receivable | $ | 1,536 | | | $ | 20,058 | |
|
| Schedule of Accounts Receivable, Allowance for Credit Loss |
The table below presents a roll forward of the Company's allowance for credit losses (amount in thousands).
| | | | | | | Beginning balance as of January 1, 2024 | $ | 3,864 | | | Accounts written off | (39) | | | Current period provision for expected credit losses | 11,018 | | | Balance as of December 31, 2024 | 14,843 | | | Current period provision for expected credit losses | 1,005 | | | Deconsolidation of PDX | (14,826) | | | Balance as of December 31, 2025 | $ | 1,022 | |
|
| Schedule of Components of Inventory |
At December 31, 2025 and 2024, the components of inventory are as follows (in thousands): | | | | | | | | | | | | | December 31,
2025 | | December 31,
2024 | | Diagnostic services testing material | $ | — | | | $ | 564 | | | Raw materials | 2 | | | 147 | | | Work in process | — | | | 65 | | | Finished goods | 68 | | | 375 | | | Inventory | $ | 70 | | | $ | 1,151 | | | Inventory valuation reserve | — | | | (8) | | | Inventory, net | $ | 70 | | | $ | 1,143 | |
|
| Schedule of Disaggregation of Deferred Revenue |
The following table disaggregates our deferred revenue by recognition period (in thousands): | | | | | | | | | | | | | As of December 31, 2025 | | As of December 31, 2024 | | Recognition Period | | | | | 0-12 Months | $ | 1,501 | | | $ | 1,698 | | | 13-24 Months | 643 | | | 784 | | | Total | $ | 2,144 | | | $ | 2,482 | |
The following table disaggregates the Company’s revenue by revenue source for Fiscal 2025 and 2024 (in thousands): | | | | | | | | | | | | | | | | | For the years ended | | Revenue by Customer Type | | December 31, 2025 | | December 31, 2024 | | Retail and others | | $ | — | | | $ | 1,492 | | | Genomic products and services | | 4,345 | | | 5,278 | | | Total revenue, net | | $ | 4,345 | | | $ | 6,770 | |
|